Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00047736 · ClinicalTrials.gov registry record · Phase 3
A Study With Tarceva and Chemotherapy vs. Chemotherapy Alone in Patients With Advanced Lung Cancer
A Phase 3 study, sponsored by Genentech.
- Completed
- Registry status
- Phase 3
- Development phase
NCT00047736: Completed Phase 3 study, sponsored by Genentech.
NCT00047736 is a Phase 3 study that has completed, run by Genentech. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00047736, a Phase 3 study, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 3
- Development phase
Study Summary
The purpose of this study is to determine if Tarceva plus standard chemotherapy is more effective than standard chemotherapy alone in the treatment of lung cancer.
Interventions
- DRUG Tarceva (erlotinib HCl)
Trial Details
| Field | Value |
|---|---|
| Start Date | 2001-07 |
| Est. Completion | 2003-07 |
| Phase | Phase 3 |
What the finished NCT00047736 record still lists
NCT00047736 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which Tarceva (erlotinib HCl) is the first listed.
NCT00047736 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00047736 about?
NCT00047736 is a clinical study titled "A Study With Tarceva and Chemotherapy vs. Chemotherapy Alone in Patients With Advanced Lung Cancer". The purpose of this study is to determine if Tarceva plus standard chemotherapy is more effective than standard chemotherapy alone in the treatment of lung cancer.
What is the current status of trial NCT00047736?
This trial is currently completed. It is a Phase 3 study. The study started on 2001-07. Estimated completion is 2003-07.
What interventions are being tested in trial NCT00047736?
The interventions under investigation include: Tarceva (erlotinib HCl) (DRUG).
Who is sponsoring clinical trial NCT00047736?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia